What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease?
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
AIMS: To define the N-terminal pro-brain natriuretic peptide (NTpBNP) normal range, assessing its cardiovascular screening characteristics in general population and higher risk subjects. METHODS AND RESULTS: A total of 2320 subjects (1392 general population and 928 high-risk) > or =45 years old, selected randomly from seven community practices, were invited to undergo clinical assessment and echocardiography and to assess NTpBNP serum levels. Of these, 1205 attended. The NTpBNP normal range was calculated and its cardiovascular screening characteristics were assessed. Age (P<0.0001) and female gender (P<0.0001) independently predicted NTpBNP levels in normal subjects. In the general population, age- and gender-stratified normal NTpBNP levels gave a negative-predictive value (NPV) of 99% in excluding left ventricular systolic dysfunction, atrial fibrillation, and valvular heart disease, and a positive predictive value of 56% in detecting any cardiovascular disease assessed. In high-risk subjects, these values were 98 and 62%, respectively. Ninety-five per cent of subjects with NTpBNP levels over four times the normal had significant cardiovascular disease with the others having renal dysfunction. CONCLUSION: Normal NTpBNP levels should be stratified by age and gender. Normal NTpBNP levels give high NPV in excluding significant cardiovascular disease. Most subjects with raised NTpBNP levels and almost all subjects with NTpBNP levels over four times the normal have significant cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Davies, M., Hobbs, F., Davis, R., Kenkre, J., Roalfe, A., Hare, R., Wosornu, D., & Lancashire, R. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05620-3 · Cited by 657
Vasan, R. S., Benjamin, E. J., Larson, M. G., Leip, E. P., Wang, T. J., Wilson, P. W. F., & Levy, D. (2002) · JAMA · doi:10.1001/jama.288.10.1252 · Cited by 493 · cited 1×
“Borderline or worse left ventricular systolic dysfunction (LVSD) was defined as LVEF ,50%, significant LVSD as LVEF ,40%, as per previous epidemiological surveys.(7,8) LV mass was calculated using the Devereux-modified American Society of Echocardiography equation,(9) with left ventricular hypertrophy (LVH) defined as…”
Method
Cited by
Irbesartan in patients with heart failure and preserved ejection fraction
Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805450 · Cited by 1,960
Mant, J., Doust, J., Roalfe, A., Barton, P., Cowie, M., Glasziou, P., Mant, D., McManus, R., Holder, R., Deeks, J., et al. (2009) · Health Technology Assessment · doi:10.3310/hta13320 · Cited by 498
Simonneau, G., Torbicki, A., Hoeper, M. M., Delcroix, M., Karlócai, K., Galiè, N., Degano, B., Bonderman, D., Kurzyna, M., Efficace, M., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00137511 · Cited by 314
Influence of Population Selection on the 99th Percentile Reference Value for Cardiac Troponin Assays
Collinson, P. O., Heung, Y. M., Gaze, D., Boa, F., Senior, R., Christenson, R., & Apple, F. S. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2011.171082 · Cited by 254
Self-citationPrognostic Value of Brain Natriuretic Peptide in Noncardiac Surgery: A Meta-analysis
Ryding, A. D. S., Kumar, S., Worthington, A. M., & Burgess, D. (2009) · Anesthesiology · doi:10.1097/aln.0b013e3181aaeb11 · Cited by 187
Metadata
- Authors
- Galasko, G. I. W., Lahiri, A., Barnes, S. C., Collinson, P., & Senior, R.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-07-21
- Volume
- 26
- Issue
- 21
- Pages
- 2269-2276
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2012781794
- Cited by
- 157
- References
- 2
- FWCI
- 10.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? https://app.cochat.ai/papers/10.1093/eurheartj/ehi410
- The paper
- Galasko, G. I. W., Lahiri, A., Barnes, S. C., Collinson, P., & Senior, R. (2005). What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? European Heart Journal. https://doi.org/10.1093/eurheartj/ehi410
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.